Emerging pharmacotherapies for Creutzfeldt-Jakob disease

Archives of Neurology

Volumn 63, Issue 4, 2006, Pages 497-501

  Korth, Carsten ^a   Peters, Peter J ^b  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORPROMAZINE; CONGO RED; DEXTRAN; FLUPIRTINE; HEPARIN; HETEROCYCLIC COMPOUND; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEPACRINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; PENTOSAN POLYSULFATE; POLYANION; PRION PROTEIN; RECOMBINANT ANTIBODY;

CLINICAL TRIAL; CREUTZFELDT JAKOB DISEASE; CYTOLOGY; DRUG PENETRATION; DRUG POTENCY; DRUG TARGETING; GENE SILENCING; HUMAN; NEUROPATHOLOGY; NEUROPROTECTION; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; REVIEW; SCRAPIE; SYMPTOMATOLOGY; TREATMENT INDICATION; UNSPECIFIED SIDE EFFECT;

ANIMALS; ANTIBODIES; CREUTZFELDT-JAKOB SYNDROME; GENE SILENCING; HETEROCYCLIC COMPOUNDS; HUMANS; MEMBRANE MICRODOMAINS; PRPC PROTEINS; PRPSC PROTEINS; RNA INTERFERENCE;

EID: 33645750334     PISSN: 00039942     EISSN: 15383687     Source Type: Journal    
DOI: 10.1001/archneur.63.4.497     Document Type: Review

References (10)

1. Prusiner SB. Prions. Proc Natl Acad Sci U S A. 1998;95:13 363-13 383.
2. Will RG. Acquired prion disease: iatrogenic CJD, variant CJD, kuru. Br Med Bull. 2003;66:255-265.
3. Mallucci G, Dickinson A, Linehan J, Klohn PC, Brandner S, Collinge J. Depleting neuronal PrP in prion infection prevents disease and reverses spongiosis. Science. 2003;302:871-874.
4. White AR, Enever P, Tayebi M, et al. Monoclonal antibodies inhibit prion replication and delay the development of prion disease. Nature. 2003;422:80-83.
5. Doh-ura K, Ishikawa K, Murakami-Kubo I, et al. Treatment of transmissible spongiform encephalopathy by intraventricular drug infusion in animal models. J Virol. 2004;78:4999-5006.
6. Otto M, Cepek L, Ratzka P, et al. Efficacy of flupirtine on cognitive function in patients with CJD: a double-blind study. Neurology. 2004;62:714-718.
7. Korth C, May BCH, Cohen FE, Prusiner SB. Acridine and phenothiazine derivatives as pharmacotherapeutics for prion disease. Proc Natl Acad Sci U S A. 2001;98:9836-9841.
8. Ryou C, Lessard P, Freyman Y, et al. In vivo efficacy of quinacrine in animal models of prion disease. Paper presented at: First International Conference of the European Network of Excellence NeuroPrion; May 24-28, 2004; Paris, France. Abstract THE-29.
9. Gayrard V, Picard-Hagen N, Viguie C, Laroute V, Andreoletti O, Toutain PL. A possible pharmacological explanation for quinacrine failure to treat prion diseases: pharmacokinetic investigations in a ovine model of scrapie. Br J Pharmacol. 2005;144:386-393.
10. Haik S, Brandel JP, Salomon D, et al. Compassionate use of quinacrine in Creutzfeldt-Jakob disease fails to show significant effects. Neurology. 2004;63:2413-2415.